Word Lung Cancer Vaccine Market Landscape Investigated by Kuick Research in New Market Study Published at MarketPublishers.com
26 Feb 2015 • by Natalie Aster
LONDON – Pharmacos keep on working upon the identification of novel targets for the development of lung cancer vaccines in order to provide effective medical care to patients. Manifold mechanisms and cancer antigens have been identified to develop new different lung cancer vaccines, which is set to assist the patients in deciding which therapeutic option best meets their needs, and also generate massive revenues for pharmacos.
Today, there are 29 lung cancer vaccines are in clinical development pipeline and the majority of them are in Phase-II clinical trials. 3 lung cancer vaccines are currently commercially available in the market.
Lung cancer vaccines will likely become a major tool in treating lung cancer in the offing owing to excellent pharmacological performance. Prophylactic lung cancer vaccines present a very good alternative on the horizon and they need to be scrupulously investigated in clinical studies. A slew of novel lung cancer vaccines are under different clinical development phases. A significant amount of data generated in clinical settings has given a measure of hope to oncologists and pharmacos to explore various forms of lung cancer vaccines. As soon as high levels of safety and efficacy of these vaccines are obtained, the process of gaining marketing approval will be pose a big problem in various countries of the world.
New research report “Global Lung Cancer Vaccine Market & Pipeline Insight 2015” drawn up by Kuick Research provides a comprehensive analysis the global lung cancer vaccine marketplace.
The study provides an all-round overview of the market including insightful information on cancer vaccines, details about their mechanism as well as innovative drug development of cancer vaccines. It discusses the market scenario as of now, sheds light on the clinical pipeline, uncovers the emerging trends and analyses the market dynamics including drivers and challenges. The research report examines global lung cancer vaccine pipeline by company and stage, covering 29 vaccines, 8 vaccines in Phase-II trials, 3 marketed vaccines such as BV NSCLC 001, Vaxira and Mycidac-C, suspended and discontinued lung cancer vaccines, besides giving insights into the progress and possibilities of personalised vaccines. An in-depth investigation of the competitive landscape including profiles of the top 8 companies is also provided, as is the outlook for the future growth of the market space.
Global Lung Cancer Vaccine Market & Pipeline Insight 2015
Published: February, 2015
Price: US$ 1,200.00
More new studies by the publisher can be found at Kuick Research page.